LIM domain kinase 1
LIMK1 is one of two LIM kinase, which were shown to be highly expressed in many types of tumors, and regulate several proteins crucial for cell division. These kinases are downstream of Rho-associated protein kinases and p21-activated protein kinases1. When LIMKs are inhibited, actin microfilaments are disorganized and microtubules are stabilized, making LIMK inhibitors promising treatment for cancers.
LIMK1 kinase assay is run on mobility shift microfluidics platform (Caliper), which provides best in industry quality of data. We routinely run services associated with this kinase including: screening, profiling, dose-response studies and kinetic measurements. Please contact us for more information.
1. Prunier C, Josserand V, Vollaire J, Beerling E, Petropoulos C, Destaing O, Montemagno C, Hurbin A, Prudent R, De Koning L, Kapur R. LIM kinase inhibitor Pyr1 reduces the growth and metastatic load of breast cancers. Cancer research. 2016 Jun 15;76(12):3541-52.